most effective glp-1 for weight loss medications Who Is a Good Candidate
Description
Curtis L, Humayun MA, Walker J, Hampton K, Partridge H
Clinical trials demonstrate that semaglutide monotherapy produces meaningful weight reductions, improved glycemic control, and cardiovascular benefits in patients with obesity and related conditions
placebo and for combination groups vs
They concluded that the net price of Zepbound would have to come down by 31% and the net price of Wegovy would have to come down by 82% for these drugs to be cost-effective at $100,000 per QALY
Included at no cost, exclusively for Emerge patients
In New Mexico, Kansas, West Virginia, Louisiana, and Mississippi, a short video or audio visit is required
